Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Expands By 27.5%

Aileron Therapeutics, Inc. (NASDAQ:ALRNGet Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 185,100 shares, a growth of 27.5% from the March 31st total of 145,200 shares. Based on an average daily trading volume, of 381,500 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.3% of the shares of the company are sold short.

ALRN opened at $0.44 on Monday. The company has a market cap of $40.03 million, a P/E ratio of -1.52 and a beta of 2.59. The business’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.58. Aileron Therapeutics has a 12 month low of $0.36 and a 12 month high of $1.40.

Aileron Therapeutics (NASDAQ:ALRNGet Rating) last announced its quarterly earnings results on Monday, March 28th. The company reported ($0.08) earnings per share (EPS) for the quarter. Analysts expect that Aileron Therapeutics will post -0.33 earnings per share for the current year.

Several research firms recently issued reports on ALRN. William Blair reissued an “outperform” rating on shares of Aileron Therapeutics in a research note on Tuesday, March 29th. Zacks Investment Research raised Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Aileron Therapeutics in a research note on Tuesday, March 29th.

A number of institutional investors have recently bought and sold shares of the business. Bailard Inc. bought a new stake in Aileron Therapeutics during the 1st quarter valued at approximately $66,000. Blair William & Co. IL boosted its position in shares of Aileron Therapeutics by 32.9% in the 4th quarter. Blair William & Co. IL now owns 1,067,489 shares of the company’s stock worth $601,000 after purchasing an additional 264,329 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Aileron Therapeutics by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 862,002 shares of the company’s stock worth $485,000 after purchasing an additional 39,056 shares in the last quarter. KCK LTD. bought a new stake in shares of Aileron Therapeutics in the 4th quarter worth approximately $362,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Aileron Therapeutics in the 4th quarter worth approximately $47,000. 36.46% of the stock is currently owned by institutional investors and hedge funds.

About Aileron Therapeutics (Get Rating)

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

See Also

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.